Patent ID: 6872738

Claim:
A method of treating a disorder selected from the group consisting of cardiovascular and cerebrovascular disorders, disorders of the central or peripheral nervous system, proliferative and inflammatory diseases, diarrheas, vomiting, radioactive irradiation, solar radiation and organ transplants, in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a product comprising at least one NO synthase inhibiting substance of the formula wherein R 0 is hydrogen or alkyl; A is wherein R 1 and R 2 are individually selected from the group consisting of hydrogen, halogen, OH alkyl of 1 to 6 carbon atoms and alkoxy of 1 to 6 carbon atoms, and R 3 is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and —COR 4 , R 4 is alkyl of 1 to 6 carbon atoms, or A is wherein R 3 is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and —COR 4 , R 4 is alkyl of 1 to 6 carbon atoms; B is selected from the group consisting of alkyl of 1 to 6 carbon atoms, phenyl, pyridinyl and a heterocycle with 5 members containing 1 to 4 heteroatoms selected from the group consisting of O, S and N, the carbons which are unsubstituted or substituted by at least one member of the group consisting of alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms and halogen; X is selected from the group consisting of —CO—N(R 3 )—X′—, —NH—CO—X′—, —CH═, —CO— and a bond, X′ is —(CH 2 ) n , n is an integer from 0 to 6; Y is selected from the group consisting of —Y′—, —CO—NH—Y′, —Y′—NH—CO, —CO—Y′—, —Y′—CO, —N(R 3 )—Y′—, —Y′—N(R 3 )—, Y′—(CH 2 —N(R 3 )—CO—, —O—Y′—, —Y′—O—; —S—Y′—, —Y′—S—, —Y′—O—Y′—, —Y′—N(R 3 )—Y′— and a bond, Y′ is —(CH 2 ) n — where n is an integer from 0 to 6; Het is a heterocycle comprising 1 to 5 heteroatoms selected from the group consisting of O, N, S and unsubstituted or substituted by at least one member of the group consisting of —X′—OR 3 , —X′—NR 3 and —X′S—R 3 , and a pharmaceutically acceptable salt thereof in association with at least one phospholipase A2 inhibiting substance, in separate form or in combination, sufficient to treat said disorder.